PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors.
Curr Drug Targets
; 17(14): 1661-1672, 2016.
Article
em En
| MEDLINE
| ID: mdl-26302797
ABSTRACT
Over the years, polo-like kinase 1 (PLK1) has garnered great interest as a therapeutic target. The PLK1 is a member of a highly conserved serine/threonine kinase family that plays pivotal roles in mitosis, cytokinesis and DNA damage response in eukaryotic cells. In this review, we summarize the functions of PLK1 during cell cycle progression, its roles in human pediatric cancer and its value as a prognostic factor. Furthermore, we introduce the advances in pharmacological inhibition and the newly chemotherapeutic development of small-molecules to target PLK1 in cancer treatment. Finally, clinical trials with PLK1 inhibitors are briefly reviewed.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Proto-Oncogênicas
/
Proteínas Serina-Treonina Quinases
/
Proteínas de Ciclo Celular
/
Bibliotecas de Moléculas Pequenas
/
Neoplasias
Tipo de estudo:
Prognostic_studies
Limite:
Child
/
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article